FAMDF (Futura Medical) Liabilities-to-Assets : 0.46 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Futura Medical Liabilities-to-Assets?

Futura Medical FAMDF -60.00% Liabilities-to-Assets is 0.46 as of Dec. 2025. The stock has 5 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Futura Medical's Total Liabilities for the quarter that ended in Dec. 2025 was $3.23 Mil. Futura Medical's Total Assets for the quarter that ended in Dec. 2025 was $6.99 Mil. Therefore, Futura Medical's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 was 0.46.

Futura Medical  (OTCPK:FAMDF) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Futura Medical Liabilities-to-Assets Related Terms

Futura Medical Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Futura Medical's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Futura Medical Liabilities-to-Assets Chart

Futura Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.27 0.54 0.34 0.46

Futura Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.18 0.34 0.45 0.46

FAMDF vs VRTX, REGN, ALNY: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, Futura Medical's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Futura Medical Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Futura Medical's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Futura Medical's Liabilities-to-Assets falls into.


Futura Medical Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Futura Medical's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Liabilities-to-Assets (A: Dec. 2025 )=Total Liabilities/Total Assets
=3.232/6.987
=0.46

Futura Medical's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 is calculated as

Liabilities-to-Assets (Q: Dec. 2025 )=Total Liabilities/Total Assets
=3.232/6.987
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.46 mean?
Futura Medical (FAMDF) has a Liabilities-to-Assets of 0.46 as of Dec. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Futura Medical and its competitors.
Is Futura Medical's Liabilities-to-Assets too high?
Futura Medical's current Liabilities-to-Assets is 0.46.
How does Futura Medical's Liabilities-to-Assets compare to VRTX and REGN?
Futura Medical's Liabilities-to-Assets of 0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Futura Medical and its competitors. Futura Medical's current Liabilities-to-Assets is 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.00 — trading 95% below its estimated fair value. The current Liabilities-to-Assets is 0.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Futura Medical (FAMDF), the current Liabilities-to-Assets is 0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Futura Medical Business Description

Other Exchanges FUMl:UKFUM:UKGYX:Germany
Address 40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.